Aurinia
Aurinia Pharmaceuticals Inc., commonly referred to as Aurinia, is a biopharmaceutical company headquartered in Canada. Founded in 2013, Aurinia focuses on developing innovative therapies for autoimmune diseases, with a particular emphasis on lupus nephritis. The company has made significant strides in the industry, notably with the launch of its flagship product, LUPKYNIS™ (voclosporin), which offers a unique mechanism of action that enhances treatment options for patients. With a strong presence in North America and expanding operations in Europe, Aurinia has established itself as a leader in the autoimmune disease sector. The company’s commitment to research and development, coupled with its strategic partnerships, has positioned it favourably in the market, earning recognition for its contributions to patient care and treatment advancements.
DitchCarbon Score
How does Aurinia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurinia's score of 24 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aurinia's reported carbon emissions
In 2023, Aurinia Pharmaceuticals Inc. reported total carbon emissions of approximately 218,430 kg CO2e. This figure represents their global emissions for the year, although specific breakdowns by scope (Scope 1, 2, or 3) were not disclosed. In 2022, the company reported emissions of about 198,740 kg CO2e, all of which were classified under Scope 2, indicating that they primarily stemmed from purchased electricity. Aurinia has not set any specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of reduction targets suggests a need for further development in their sustainability strategy. The emissions data is not cascaded from any parent organization, indicating that Aurinia Pharmaceuticals Inc. is independently reporting its emissions without inherited data from a corporate family relationship. As the company continues to grow, it may benefit from establishing clear climate commitments and reduction strategies to enhance its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | - |
| Scope 2 | 198,740 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aurinia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
